PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.

PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
复制标题

DOI:
10.1016/j.celrep.2018.08.002
复制
发表时间:
2018-09-04
期刊:
影响因子:
8.8
通讯作者:
Nimer SD
Nimer SD
中科院分区:
生物学1区
文献类型:
--
作者:
Hamard PJ;Santiago GE;Liu F;Karl DL;Martinez C;Man N;Mookhtiar AK;Duffort S;Greenblatt S;Verdun RE;Nimer SD

文献摘要

参考文献

被引文献

相似文献

蛋白质精氨酸甲基转移酶5(PRMT 5)在许多癌症类型中过表达,并且是其中几种癌症(包括白血病和淋巴瘤)的有希望的治疗靶点。然而,我们和其他人已经报道了PRMT 5对正常生理是必不可少的。这种依赖性在治疗环境中可能成为剂量限制性的,从而阻碍了对组合方法的研究。在这里,我们报告说,PRMT 5耗尽或抑制损害同源重组(HR)DNA修复,导致DNA损伤积累,p53激活,细胞周期停滞和细胞死亡。PRMT 5对称二甲基化组蛋白和非组蛋白底物,包括RNA剪接机制的几种组分。我们发现,PRMT 5耗尽或抑制诱导异常剪接的多功能表观遗传和DNA修复因子TIP 60/KAT 5,这选择性地影响其赖氨酸乙酰转移酶活性,并导致受损的HR。由于HR缺乏敏感细胞PARP抑制剂,我们在这里证明,PRMT 5和PARP抑制剂对急性髓性白血病细胞有协同作用。
Protein arginine methyltransferase 5 (PRMT5) is overexpressed in many cancer types and is a promising therapeutic target for several of them, including leukemia and lymphoma. However, we and others have reported that PRMT5 is essential for normal physiology. This dependence may become dose-limiting in a therapeutic setting, warranting the search for combinatorial approaches. Here we report that PRMT5 depletion or inhibition impairs homologous recombination (HR) DNA repair, leading to DNA damage accumulation, p53 activation, cell cycle arrest and cell death. PRMT5 symmetrically dimethylates histone and non-histone substrates, including several components of the RNA splicing machinery. We find that PRMT5 depletion or inhibition induces aberrant splicing of the multifunctional epigenetic and DNA repair factor TIP60/KAT5, which selectively affects its lysine acetyltransferase activity and leads to impaired HR. As HR-deficiency sensitizes cells to PARP inhibitors, we demonstrate here that PRMT5 and PARP inhibitors have synergistic effects on acute myeloid leukemia cells.
DOI: 10.1016/j.molcel.2017.01.019
发表时间: 2017-03-02
期刊: Molecular cell
影响因子: 16
作者:
Clarke TL;Sanchez-Bailon MP;Chiang K;Reynolds JJ;Herrero-Ruiz J;Bandeiras TM;Matias PM;Maslen SL;Skehel JM;Stewart GS;Davies CC
通讯作者: Davies CC
DOI: 10.1038/onc.2012.38
发表时间: 2013-01-01
期刊: ONCOGENE
影响因子: 8
作者:
Allende-Vega, N.;Dayal, S.;Saville, M. K.
通讯作者: Saville, M. K.
DOI: 10.1038/nm.4097
发表时间: 2016-06
期刊: Nature medicine
影响因子: 82.9
作者:
Lee SC;Dvinge H;Kim E;Cho H;Micol JB;Chung YR;Durham BH;Yoshimi A;Kim YJ;Thomas M;Lobry C;Chen CW;Pastore A;Taylor J;Wang X;Krivtsov A;Armstrong SA;Palacino J;Buonamici S;Smith PG;Bradley RK;Abdel-Wahab O
通讯作者: Abdel-Wahab O
DOI: 10.1126/science.aad5214
发表时间: 2016-03-11
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Kryukov GV;Wilson FH;Ruth JR;Paulk J;Tsherniak A;Marlow SE;Vazquez F;Weir BA;Fitzgerald ME;Tanaka M;Bielski CM;Scott JM;Dennis C;Cowley GS;Boehm JS;Root DE;Golub TR;Clish CB;Bradner JE;Hahn WC;Garraway LA
通讯作者: Garraway LA
DOI: 10.1038/nm.3993
发表时间: 2015-12-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Esposito, Maria Teresa;Zhao, Lu;So, Chi Wai Eric
通讯作者: So, Chi Wai Eric